Genmab
GMAB
274 hedge funds and large institutions have $2.23B invested in Genmab in 2026 Q1 according to their latest regulatory filings, with 44 funds opening new positions, 105 increasing their positions, 94 reducing their positions, and 59 closing their positions.
1,533% more call options, than puts
Call options by funds: $16M | Put options by funds: $977K
12% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 94
1.33% more ownership
Funds ownership: 11.4% → 12.74% (+1.3%)
1% less capital invested
Capital invested by funds: $2.26B → $2.23B (-$23.4M)
6% less funds holding
Funds holding: 293 → 274 (-19)
25% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 59
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$110M |
| 2 |
DM
Deerfield Management
New York
|
+$73.8M |
| 3 |
Two Sigma Investments
New York
|
+$43.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$34.8M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$33.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAG
Orbis Allan Gray
Hamilton,
Bermuda
|
-$44.7M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$39.6M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.4M |
| 4 |
Goldman Sachs
New York
|
-$12M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$11.7M |
GMAB Hedge Fund Activity: Q1 2026 in Review
274 of the 8,180 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2026, worth a combined $2.23B — down 1% from $2.26B a quarter earlier.
Sellers outnumbered buyers: 59 funds closed out of GMAB and 44 opened new positions — a net loss of 15 holders — while 94 trimmed existing stakes and 105 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $110M. The largest seller was Orbis Allan Gray, cutting an estimated $44.7M.
- 274 institutional investors held Genmab (GMAB) as of Q1 2026, down from 293 in Q4 2025.
- Funds reported $2.23B of Genmab stock for Q1 2026, down 1% quarter-over-quarter.
- 44 funds opened new Genmab positions in Q1 2026 and 59 closed out, a net change of -15 holders.
- The largest Genmab buyer in Q1 2026 was Deep Track Capital, an estimated $110M added.
- The largest Genmab seller in Q1 2026 was Orbis Allan Gray, an estimated $44.7M sold.
Based on aggregated 13F filings for Q1 2026.